- Home
- LYEL vs BWAY Comparison
LYEL vs BWAY Comparison
Compare LYEL & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- BWAY
- Stock Information
- Founded
- LYEL 2018
- BWAY 2003
- Country
- LYEL United States
- BWAY Israel
- Employees
- LYEL N/A
- BWAY N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- LYEL Health Care
- BWAY Health Care
- Exchange
- LYEL Nasdaq
- BWAY Nasdaq
- Market Cap
- LYEL 207.7M
- BWAY 207.4M
- IPO Year
- LYEL 2021
- BWAY 2019
- Fundamental
- Price
- LYEL $0.40
- BWAY $8.76
- Analyst Decision
- LYEL Sell
- BWAY Strong Buy
- Analyst Count
- LYEL 2
- BWAY 3
- Target Price
- LYEL $1.00
- BWAY $13.17
- AVG Volume (30 Days)
- LYEL 648.7K
- BWAY 24.4K
- Earning Date
- LYEL 05-20-2025
- BWAY 05-13-2025
- Dividend Yield
- LYEL N/A
- BWAY N/A
- EPS Growth
- LYEL N/A
- BWAY N/A
- EPS
- LYEL N/A
- BWAY 0.06
- Revenue
- LYEL $61,000.00
- BWAY $41,016,000.00
- Revenue This Year
- LYEL N/A
- BWAY $351.53
- Revenue Next Year
- LYEL N/A
- BWAY $21.84
- P/E Ratio
- LYEL N/A
- BWAY $57.37
- Revenue Growth
- LYEL N/A
- BWAY 29.04
- 52 Week Low
- LYEL $0.39
- BWAY $5.13
- 52 Week High
- LYEL $2.88
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- LYEL 37.66
- BWAY 47.80
- Support Level
- LYEL $0.41
- BWAY $8.61
- Resistance Level
- LYEL $0.51
- BWAY $9.09
- Average True Range (ATR)
- LYEL 0.05
- BWAY 0.38
- MACD
- LYEL 0.00
- BWAY 0.05
- Stochastic Oscillator
- LYEL 8.33
- BWAY 58.73
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.